Laprituximab emtansineLaprituximab emtansine (Synonyms: IMGN-289
J2898A-SMCC-DM1)
MedChemExpress (MCE)
HY-P99685
1622327-37-0
IMGN-289
J2898A-SMCC-DM1)
请将产品存放在分析证书上推荐的条件下。
美国大陆的室温;其他地方可能有所不同。
Laprituximab emtansine (IMGN-289) 是一种靶向 HER1 的免疫毒素。Laprituximab emtansine 是一种 EGFR 抗体-药物偶联物 (ADC),由 J2898A 抗体、DM1 (抗微管剂) 和 SMCC 硫醚连接子组成。Laprituximab emtansine 可用于癌症研究。
Laprituximab emtansine (IMGN-289) 是一种针对 HER1 的免疫毒素。Laprituximab emtansine 是一种 EGFR 抗体-药物偶联物 (ADC),由 J2898A 抗体、DM1(抗微管剂)和 SMCC 硫醚接头组成。Laprituximab emtansine 可用于癌症研究[1][2][3]。
Laprituximab emtansine 显示出对 HNSCC 细胞系的抗克隆形成和抗增殖活性,IC50s 为 0.003 nM-1.74 nM[3]。 Laprituximab emtansine 对 NSCLC 细胞系和 EGFR 突变 HCC827 细胞系具有细胞毒性[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Laprituximab emtansine (1-5 mg/kg,静脉注射) 在 EGFR 阳性 SCCHN 异种移植模型中导致肿瘤消退[4]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
HER1
| | | | | | | | |
| | | | | |
[1]. Moradi-Kalbolandi S, et al. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. J Pharm Pharmacol. 2018 Jul
70(7):841-854.
[2]. Yulius Y. et al. Abstract 4513: IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors. Cancer Res 1 October 2014
74 (19_Supplement): 4513.
[3]. Hyunseok Kang, et al. Antitumor effect of IMGN289, an anti-EGFR antibody-drug conjugate (ADC), in preclinical models of head and neck squamous cell carcinomas (HNSCC). Journal of Clinical Oncology. 2014. 32, no. 15_suppl.
[4]. Jose F. Ponte, et al. Abstract 5483: Preclinical evaluation of IMGN289, an anti-EGFR antibody-maytansinoid conjugate for the treatment of squamous cell carcinoma of the head and neck. Cancer Res (2013) 73 (8_Supplement): 5483.